Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis. by Wang Ya-Feng et al.
 
Phyllaemblicin B inhibits Coxsackie Virus B3 induced apoptosis 
and myocarditis 
 
Wang Ya-Feng1,2,Wang Xiao-Yan1,2, Ren Zhe1,2,Qian Chui-Wen1,2,Li Yi-Cheng1,2, Kaio 
Kitazato3,Wang Qing-Duan4,Zhang Yan4,Zheng Li-Yun4,Jiang Jin-Hua4, Yang 
Chong-Ren5, Liu Qing5，Zhang Ying-Jun5,Wang Yi-Fei1,2 
(1Jinan University，Guangdong, Guangzhou, 510630,China; 2National Engineering 
Research Center of Genetic Medicine，Guangdong, Guangzhou, 
510630,China;3Laboratory of Molecular Biology of Infectious Agents, Department of 
Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, 
Nagasaki University, Nagasaki, Japan;4Henan Institute of Medical 
Sciences,Henan,Zhengzhou,450000,China;5Kunming Institute of Botany, the Chinese 
Academy of Sciences,Yunnan,Kunming,650204,China.) 
 
Abstract 
Coxsackie virus B3 (CVB3) is believed to be a major contributor to viral myocarditis 
since virus-associated apoptosis plays a role in the pathogenesis of experimental 
myocarditis. In this study, we investigated the in vitro and in vivo antiviral activities of 
Phyllaemblicin B, the main ellagitannin compound isolated from Phyllanthus emblica, a 
Chinese herb medicine, against CVB3. Herein we report Phyllaemblicin B inhibited 
CVB3-mediated cytopathic effects on HeLa cells with an IC50 value of 7.75±0.15 µg/mL. 
In an in vivo assay, treatment with 12 mg·kg-1·d-1 Phyllaemblicin B reduced cardiac 
CVB3 titers, decreased the activities of LDH and CK in murine serum, and alleviated 
pathological damages of cardiac muscle in myocarditic mice. Moreover, Phyllaemblicin 
B clearly inhibited CVB3-associated apoptosis effects both in vitro and in vivo. These 
results show that Phyllaemblicin B exerts significant antiviral activities against CVB3. 
Therefore, Phyllaemblicin B may represent a potential therapeutic agent for viral 
myocarditis.  
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Coxsackie virus B3 (CVB3) is a member of the genus Enterovirus of the 
Picornaviridae family that contains a single-stranded, positive-sense RNA genome. It is a 
cardiotropic virus known to induce viral myocarditis (Kuhl et al. 2005) in children and 
young people, which is a common cause of acute heart failure and dilated 
cardiomyopathy (DCM). Unrecognized viral myocarditis develops into DCM in 
two-thirds of the patients. Several studies suggest that not only viral infection of the 
myocardium itself but the associated inflammatory responses are determinants of the 
virus-associated myocardial damage (Chow et al. 1992; McManus et al. 1993; Huber et al. 
1999; Henke et al. 1995; Antoniak et al. 2008). However, until now, the mechanisms 
detailing how CVB3 causes myocarditis are not well characterized nor are there 
virus-specific preventive or therapeutic procedures available to protect humans against 
CVB3-induced heart diseases.    
Apoptosis, programmed cell death, is a distinct type of cell death, which is 
characterized by a series of typical morphological features (Kerr et al. 1972) and 
regulated by several factors. Previous studies show that apoptotic events occur frequently 
during CVB3 infections under in vitro as well as in vivo conditions (Feuer et al. 2003; 
Saraste et al. 2003; Yuan et al. 2003; Carthy et al. 1998). Recently, it has been 
demonstrated that one hallmark of CVB3-induced pathogenesis is apoptosis; hence, the 
activation of apoptotic pathways during CVB3 infection is of a growing interest 
(Cunningham et al. 2003). The mitochondria-mediated pathway is commonly believed to 
 
be associated with apoptosis induced by CVB3. Mitochondria have increasingly become 
recognized as central regulators of caspase activation during CVB3 infection. Caspase 
activation (Martin et al. 2007) and mitochondrial release of cytochrome c (Carthy et al. 
2003) may be an important early event in CVB3 infection. Bcl-2 is an antiapoptotic 
molecule which regulates mitochondrial permeability and release of cytochrome c into 
the cytosol. Once cytochrome c is released, caspase is activated and apoptosis is triggered 
via the mitochondria-mediated pathway (Si et al. 2005). However, although some 
pathogenic pathways of CVB3 are well documented, details regarding CVB3 
involvement in the apoptotic processes remain unclear.  
Phyllaemblicin B is the main ellagitannin compound isolated from the roots of 
Phyllanthus emblica L. (Euphorbiaceae), which is a shrub or tree that grows in 
subtropical and tropical areas of the People’s Republic of China, India, Indonesia, and the 
Malay Peninsula (Zhang et al. 2001). It is widely used in many local traditional medicinal 
systems, such as Chinese herbal medicine, Tibetan medicine, and Ayurvedic medicine for 
its anti-inflammatory and antipyretic effects. Minority groups living in the southwest of 
China use the roots of P. emblica for the treatment of eczema, and in Nepal it is used as 
an astringent and hematostatic agent (Xia et al. 1997). Recently, anti-CVB3 activity of 
Phyllaemblicin B has shown by our group in order to determine its possible 
pharmacological mechanism, in this study, we further investigated its activities against 
CVB3 in vitro and in vivo.  
Materials and methods 
1. Agents 
Phyllaemblicin B was obtained from the Laboratory of Phytochemistry, Kunming 
 
Institute of Botany, Chinese Academy of Sciences, (China) (Zhang et al. 2000). The 
chemical structure is shown in Figure 1. 
3-[4,5-Dimethyl-2-thiazolyl]-2,5-diphenyl-2-tetrazolium bromide (MTT) was purchased 
from Sigma. Ribavirin (injection, 100 mg/mL) was purchased from the Guangzhou 
Shiqiao Parmaceutical Group Corporation (lot no. 0705072). Twice distilled deionized 
water was used throughout the experiments.  
2. Virus and cell cultures 
Coxsackie virus B3 Nancy strain, which was generously provided by the Wuhan 
Institute of Virology, Chinese Academy of Sciences, was propagated in HeLa cell 
monolayers and stored at -80 °C until use. Viral titers were determined by TCID50 assays, 
and infections with CVB3 were performed at 100 TCID50. HeLa cells were obtained from 
the American Type Culture Collection and routinely grown in complete medium 
(Dulbecco’s modified Eagle’s medium [DMEM; Gibco] supplemented with 10% 
heat-inactivated newborn calf serum, 0.1% L-glutamine, 100U/mL penicillin, and 0.1 
mg/mL streptomycin) at 37 °C in a humid atmosphere with 5% CO2. The test medium 
used for the cytotoxic assay as well as for antiviral assays contained 2% of the calf 
serum.  
3. Animals 
BALB/c mice (4 weeks of age, between 14 to 16 g, male) were purchased and 
maintained at the Experimental Animal Center, Zhengzhou University (clean grade, 
certificate no. 0009706). They were housed in constant conditions at a temperature of 23 
± 1 °C, a humidity level of 40 ± 5%, and on a 12-h light/12-h dark cycle. They had free 
access to pellet food and tap water.  
 
4. In vitro antiviral activity experiments 
4.1 Determination of cytotoxicity 
The cytotoxicity of the compound was determined using a quantitative colorimetric 
MTT [(3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide)] assay 
(Mosmann, 1983). Briefly, HeLa cells were seeded in 96-well plates and grown to 
monolayers. After removal of the growth medium, serial two-fold dilutions of the 
compound in 100 µL test medium were added. The plates were incubated at 37 °C and 
checked daily by light microscopy. After 48 h of incubation, 20 µL MTT (0.5 mg/mL) 
was added to each well and allowed to react for 4 h. After removal of supernatant, 100 µL 
of DMSO were added to each well. Plates were incubated at room temperature for 30 min 
and the optical density (OD) was measured at the dual wavelengths of 570 and 630 nm. 
The 50% cytotoxic concentration (CC50) was defined as the concentration of compound 
required to reduce the viability of untreated cell cultures by 50%. The mean 
dose-response curve of at least three tests was used to calculate the CC50. 
4.2 Antiviral activity  
HeLa cells were grown in 96-well plates and were allowed to form monolayers. Fifty 
microliters of viral suspensions containing 100 TCID50 of the virus stock and an equal 
volume of medium containing various concentrations of the test compound at doses 
below the CC50 were added to each well. Non-infected and infected cells without the test 
compound served as a cell and virus controls, respectively. Ribavirin (RBV) was used as 
a reference compound. When virus control cells showed the maximum cytopathic effect, 
the antiviral effect was determined using the MTT assay following the protocol described 
above (Determination of cytotoxicity). All data were analyzed and the half-maximal 
 
inhibitory concentration (IC50) was calculated. The therapeutic index (TI) was determined 
from CC50/IC50.  
4.3 Fluorescence activated cell sorting (FACS) for detection of apoptosis 
Apoptosis was detected by using Annexin V/ propidium iodide (PI) staining. In brief, 
HeLa cells infected with CVB3 were treated with the test compound for 24 h, according 
to the (IC50). After removing the supernatant, cells were digested by trypsin (0.05%) and 
washed three times with ice-cold phosphate-buffered saline (PBS). The cells were 
re-suspended and stained with Annexin V-FITC and PI. The fresh samples were analyzed 
for apoptosis by FACS.  
4.4 Two-dimensional gel electrophoresis (2-DE) 
Treated (25 µg/mL Phyllaemblicin B + CVB3) and control (DMEM + CVB3) samples 
were harvested, washed three times with ice-cold wash buffer (10 µM Tris–HCl, 250 µM 
sucrose, pH 7.0), and lysed with a buffer containing 8 M Urea, 4% CHAPS, 2% IPG 
buffer, and 0.2mg/mL PMSF for 30 minutes at 4 °C with occasional vortex mixing. The 
insoluble material was removed by centrifugation (12,000 × g) for 30 min at 4 °C and the 
protein concentrations were determined by the Bradford assay. Samples were frozen at 
-80 °C, and thawed immediately before use. In the first dimension (isoelectric focusing) 
total proteins (130 µg) were mixed with up to 250 µL of rehydration solution (8 M urea, 
2% CHAPS, 20 mM DTT and 0.5% IPG buffer) and separated by isoelectric focusing 
(IEF) using Immobilized pH Gradient (IPG) drystrips with a pH range of 3-10 on an 
Ettan IPGphor 3 (General Electric Company, USA) with a programmed voltage gradient. 
Following IEF separation, gel strips were subjected to a two-step equilibration and 
resolved by 12.5% SDS-PAGE in the second dimension. Gels were stained with silver 
 
nitrate overnight and gel images were scanned and analyzed using Image Master 2D 
Platinum 6.0 (GE Healthcare, Uppsala, Sweden). The quantity of each spot in a gel was 
normalized as a percentage of the total quantity of all spots in that gel and used for 
comparison. Only those protein spots that showed consistent and significant differences 
(more than 1.5-fold) were selected for analysis by mass spectrometry (MS). 
4.5 Protein digestion 
For MS analysis, protein spots from polyacrylamide gels were excised, rinsed twice 
with deionized water (ddH2O), destained in a 1:1 solution of 30 mM potassium 
ferricyanide, and then equilibrated in 50 mM ammonium bicarbonate to pH 8.0. After 
hydrating with acetonitrile and drying in a SpeedVac, gel spots were rehydrated in a 
minimal volume of sequencing grade porcine trypsin solution (20 µg/mL in 25 mM 
NH4HCO3) and incubated at 37 °C overnight. Supernatants were extracted once with 
extraction buffer (67% acetonitrile containing 1% trifluoroacetic acid). The peptide 
extracted and the supernatant of the gel spot was combined and completely dried. Protein 
digested extracts (tryptic peptides) were resuspended in 5 µL of 0.1% trifluoroacetic acid, 
then the peptide samples were mixed (1:1 ratio) with a saturated solution of 
α-cyano-4-hydroxy-trans-cinnamic acid in 50% acetonitrile containing 0.1% 
trifluoroacetic acid. Aliquots (0.8 µL) were spotted onto a stainless steel sample target 
plate.  
4.6 MALDI-TOF/TOF analysis 
  Peptide mass spectra was obtained on an Applied Biosystem Sciex 4800 MALDI- 
TOF/TOF mass spectrometer. Data were acquired in a positive MS reflector using a 
CalMix5 standard to calibrate the instrument (ABI4700 Calibration Mixture). Mass 
 
spectra was obtained from each sample spot by accumulation of 600-800 laser shots in a 
900-4000 mass range. For MS/MS spectra, the five most abundant precursor ions per 
sample were selected for subsequent fragmentation and 900-1200 laser shots were 
accumulated per precursor ion. The criterion for precursor selection was a minimum S/N 
of 50. Both the MS and MS/MS spectra for each spot were combined and submitted to 
the MASCOT search engine (V2.1, Matrix Science, U.K.) using GPS Explorer software 
(V3.6, Applied Biosystems) and were scanned against the following parameters: IPI 
Human database (V3.36), Homo sapiens (human) taxonomy, tryptic digests, one missed 
cleavage site, partial modification of cysteine (carboamidomethylated) and methionine 
(oxidized), no fixed modifications, MS tolerance of 30-60 ppm, MS/MS tolerance of 
0.2-0.3 Da. Known contaminant ions (keratin) were excluded. A total of 69,012 
sequences and 29,002,682 residues in the database were actually searched. MASCOT 
protein scores > 61 (based on combined MS and MS/MS spectra) were considered 
statistically significant (p < 0.05). 
4.7 RNA isolation and real-time RT-PCR      
Preparation and isolation of total RNA from cell samples were performed using TRIzol 
Reagent (Invitrogen, USA). One microgram of total RNA was reverse transcribed to yield 
single-stranded cDNA by RevertAid™ M-MuLV Reverse Transcriptase (Fermentas), 
oligo(dT)18 (Invitrogen) and a pool of dNTPs (TaKaRa). cDNAs obtained from reverse 
transcription were stored at -20 °C. For real-time PCR, SYBR Premix Ex Taq™ (TaKaRa) 
was used according to the manufacturer’s protocol. A set of three genes (encoding 
proteins caspase-3, bcl-2, and GAPDH) were analyzed for their expression patterns. 
Primer pairs were designed using Primer Premier 5 and are listed as following: caspase-3, 
 
forward primer 5’-TGAGGCGGTTGTAGAAGAG-3’; reverse primer 
5’-TAATGAGAATGGGGGAAGA-3’, bcl-2, forward primer 
5’-GATTGATGGGATCGTTGCCTTA-3’; reverse primer 
5’-CCTTGGCATGAGATGCAGGA-3’, GAPDH, forward primer 
5’-AACGGATTTGGTCGTATTGGG-3’; reverse primer 5’- 
TCGCTCCTGGAAGATGGTGAT -3’. Each real-time PCR reaction was performed for 
40 cycles at 95 °C for 1 min, 95 °C for 15 s, 58 °C for 15 s, and 72 °C for 40 s. The 
reactions were carried out in an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems). The relative expression levels of the target genes were normalized to the 
housekeeping gene GAPDH and were calculated using the formula (Livak and 
Schmittgen, 2001): Rel Exp = 2 (-∆∆CT) = 2-[( CTsample-CThousekeepinggene)-(CTvirus-CThousekeepinggene)]. 
Each real-time PCR reaction was performed in triplicate. 
4.8 Western blot 
Cell samples, either untreated or treated with different experimental reagents, were 
harvested, rinsed twice in ice-cold PBS, and kept on ice for 30 minutes in cell lysis buffer 
(Beyotime Biotechnology, China) with 1 mM PMSF (CHILE, USA) while agitating 
constantly. The lysates were centrifuged at 12,000 × g at 4 °C for 15 min and the protein 
concentration of the supernatant was measured using the BCA (bicinchoninic acid) 
protein assay kit (Beyotime Biotechnology, China). Samples were either applied 
immediately or stored at -80 °C until use. Equal amounts of protein (50 µg) were loaded 
on a 12% SDS-polyacrylamide gel for electrophoresis and subsequently transferred to 
PVDF membranes (Millipore, USA). Membranes were blocked at room temperature for 2 
h with a 5% nonfat dry milk solution containing 0.1% Tween 20 and incubated at 4 °C 
 
overnight with antibodies against rabbit caspase-3 (ABZOOM, USA), bcl-2 
(EPITOMICS, USA) and mouse β-actin (ProteinTech Group, Inc, USA). After three 
10-min washes in TBST, the membranes were incubated for 2 h at room temperature with 
a secondary antibody in blocking solution. Protein bands were visualized with an 
enhanced chemiluminescence (ECL) detection system according to the manufacturer’s 
protocol (Paragon Biotech, China). Any differences in protein loading were normalized to 
corresponding levels of β-actin control.      
5. In vivo antiviral activity experiments 
5.1 Experimental design and antiviral therapy 
In this study, 90 male BALB/c mice of 4-6 weeks in age were randomly divided into 
six groups of fifteen each. Of which, 75 mice were infected by intraperitoneal injection 
with 0.2 mL physiological saline containing 100TCID50 of purified CVB3, 15 mice were 
not infected and used as normal controls. Sixty inoculated mice were injected 
intravenously with Phyllaemblicin B at a dose of 12 mg·kg-1·d-1, 8 mg·kg-1·d-1, 4 
mg·kg-1·d-1, or with Ribavirin (RBV) at a dose of 125 mg·kg-1·d-1 daily for seven days 
and observed carefully. Fifteen of the inoculated mice were given 0.9% physiological 
saline by intravenous injection daily and used as infected controls. Mice were sacrificed 
on day eight post-infection. Blood was collected from the eye sockets and separated into 
serum in order to detect the activities of several biochemical markers, such as creatine 
kinase (CK) and lactic dehydrogenase (LDH) by using commercially available kits 
(Nanjing Jiancheng Biology Engineer Institute, China) according to the manufacturer’s 
protocol to identify myocardial injury. The heart was divided into two parts, one part was 
homogenized in DMEM to determine virus titers by TCID50 assays, and the other part 
 
was fixed for further histological, immunohistochemical, and terminal 
transferase-mediated DNA nick end-labeling (TUNEL) examinations.   
5.2 Virus titers of the heart 
Mice were sacrificed eight days post-infection. The hearts were removed, washed with 
physiological saline, and homogenized aseptically in DMEM. Homogenates were 
centrifuged at 2000 × g for 10 min at 4 °C. Virus titers were measured in 10-fold serial 
dilutions of the supernatant in DMEM by TCID50 assays in HeLa cells. 
5.3 Histology 
Histology was performed to examine myocardial injury and inflammatory lesions. 
Mice were sacrificed eight days post-infection. Hearts were dissected from the mice, 
fixed in 10% formalin solution, embedded in paraffin, sectioned serially to a thickness of 
3 µm, and stained with hematoxylin-eosin (HE). HE-stained sections were blindly and 
independently examined under a light microscope for signs of myocarditis. Photographs 
were taken with a camera. 
5.4 Measurement of apoptosis 
Cells undergoing apoptosis were evaluated by TUNEL assays using the DeadEnd™ 
Fluorometric TUNEL System (Promega, USA). In brief, deparaffinized myocardial 
sections were digested with proteinase-K to expose the DNA. Any DNA strand breaks 
were labeled using terminal transferase with ddUTP molecules conjugated to alkaline 
phosphatase and visualized immunohistochemically. The TUNEL-positive apoptotic 
cardiomyocyte nuclei were examined under a fluorescence microscope using a standard 
fluorescein filter set at 520 ± 20nm. 
5.5 Immunohistochemistry 
 
Three-micrometer serial sections were cut from paraffin-embedded tissue blocks, 
deparaffinized through a graded series of alcohol, and heat-treated in a microwave oven 
for citrate antigen retrieval. Having been blocked in 5% bovine serum albumin (BSA) for 
30 min, the sections were incubated at 4 °C overnight with the primary antibody against 
rabbit caspase-3 or bcl-2. After washing three times with PBS, slides were incubated with 
the second antibody. Bound immunoglobulins were detected by the ABC method using 
commercially available kits (Wuhan Boster Biological Technology, China).  
6. Statistical analysis 
Quantitative results were given as mean ± SD and statistical significance were 
determined by one-way analysis of the t test. For all tests, P values of less than 0.05 were 
considered statistically significant. Statistical analyses were carried out using SPSS 9.0 
software (SPSS Inc., Chicago, IL, USA). 
Results 
1. Phyllaemblicin B has potent activity against CVB3 replication in vitro  
The cytotoxicity and antiviral activity of Phyllaemblicin B against CVB3 were 
examined in HeLa cells, and the results are presented in Table 1. The TC50 and IC50 of 
Phyllaemblicin B were 50.30±1.59 µg/mL and 7.75±0.15 µg/mL, respectively. In 
antivirus assay, the therapeutic index (TI) of Phyllaemblicin B and Ribavirin were 
6.49±0.09 and 3.85±0.11, respectively.  
2. Phyllaemblicin B can strongly inhibit CVB3-induced apoptosis in 
vitro 
HeLa cells infected with CVB3 were incubated with 25 µg/mL Phyllaemblicin B and 
125µg/mL Ribavirin respectively, stained with Annexin V/PI, and harvested to evaluate 
 
apoptotic changes. The results are summarized in Fig. 2. The apoptosis rate in cells 
treated with Phyllaemblicin B and Ribavirin were significantly lower than the infected 
controls, suggesting that Phyllaemblicin B can strongly inhibit apoptosis induced by 
CVB3.  
3. Proteome analysis CVB3-infection cells with or without 
Phyllaemblicin B treatment 
The protein expression profiles of treated and control groups in the context of CVB3 
infection were analyzed by 2-DE and MALDI-TOF/TOF MS (Fig. 3A). More than 90% 
of overlapped protein spots were achieved in parallel gels from the same group, 
indicating that the spots used for differential analysis was reproducible. Fifty proteins 
showed altered expression compared with the infected control group, of which three 
proteins were identified as having >2-flod change. As shown in Table 2, 
MALDI-TOF/TOF MS analysis identified each of the three proteins. After 
Phyllaemblicin B treatment, proteins SDHA, GPX1 and TRAP1 were significantly 
upregulated (Fig. 3B).  
4. Phyllaemblicin B can significantly alter transcription levels of 
apoptosis-related genes in vitro 
Two apoptosis-related genes, caspase-3 and bcl-2 were chosen for quantitative analysis 
of their expression levels in the treated and control groups using a real-time RT-PCR. 
The expression level of each gene was normalized to the house keeping gene, GAPDH., 
Treated levels were compared against those of controls using the relative quantification 
(2-ΔΔCT) method. As shown in Fig. 4, the caspase-3 and bcl-2 values of the treated groups 
were 0.13- and 2.77-fold, respectively, of the GAPDH transcript control. Phyllaemblicin 
 
B reduced the amount of caspase-3 mRNA and markedly increased the bcl-2 mRNA level 
in treated groups in contrast to infected control groups. The quantitative PCR data were 
corroborated by Western blot analysis, expression of caspase-3 was significantly reduced 
upon treatment with Phyllaemblicin B, while bcl-2 expression was significantly elevated 
when compared with infected controls (Fig. 5). These results suggest that apoptosis 
induced by CVB3 could be inhibited strongly by Phyllaemblicin B. 
5. Effects of Phyllaemblicin B on the level of serum enzymes LDH and 
CK in CVB3-infected mice 
The activities of lactate dehydrogenase (LDH) and Creatine Kinase (CK) in mouse 
serum were significantly enhanced at eight days after CVB3 infection. In the treated 
group, Phyllaemblicin B and Ribavirin resulted in an obvious decrease in the activities of 
LDH and CK compared with the infected group. The results are shown in Fig. 6. 
6. Effects of Phyllaemblicin B on CVB3 replication in infected mice 
Virus titers in hearts of CVB3-infected mice peaked on day eight post-infection. 
Wheras, the virus titers of Phyllaemblicin B-treated groups and Ribavirin-treated guoups 
were much lower than those of the untreated-control groups (Fig. 7). These results 
indicate that Phyllaemblicin B has potent activity against CVB3 replication in infected 
mice. 
7. Effects of Phyllaemblicin B on CVB3-induced myocarditis in mice 
Infection with the CVB3 caused severe myocarditis in mice, but death and weight loss 
did not occur. The pathological process was often accompanied by mononuclear cell 
inflammation and the appearance of multiple foci in necrotic cardiomyocyte (Fig. 8B), in 
contrast to the normal group, which the structural arrangement of myocardium of was 
 
clear, i.e., the cell nucleolus was obvious and the cytoplasm was enriched (Fig. 8A). In 
groups treated with Phyllaemblicin B or Ribavirin, the damage to the myocardium was 
relieved and the area of necrosis and inflammatory infiltrates was significantly decreased 
compared with non-treated, infected animals (Fig. 8C-F).  
8. Phyllaemblicin B can significantly reduce CVB3-induced apoptosis of 
cardiomyocytes in infected mice 
In this study, we identified apoptotic cells in the myocardium by using fluorescent 
labeling of DNA strand breaks. There were very few apoptotic cardiomyocyte nuclei in 
normal groups. But in infected controls, we identified many more TUNEL-positive cells 
throughout the myocardium. In the Phyllaemblicin B-treated groups (12 mg·kg-1·d-1), the 
amount of TUNEL-positive cardiomyocyte was decreased significantly (Fig. 9). The 
heart tissues were also analyzed immunohistochemically to determine the expression of 
apoptosis-related proteins. As shown in Fig. 10, treatment with Phyllaemblicin B notably 
decreased the expression levels of caspase-3 while increasing bcl-2 expression compared 
with non-treated, infected groups.  
Discussion 
Phyllaemblicin B is the main ellagitannin compound isolated from the roots of 
Phyllanthus emblica L. (Euphorbiaceae) and its biological effects have not been widely 
studied. In this study, the first time to demonstrate that Phyllaemblicin B has potent 
anti-CVB3 activities in vitro and in vivo and can significantly inhibit CVB3-induced 
apoptosis and myocarditis. 
It is well known that viral myocarditis is mainly caused by coxsackie virus B3. Usually 
it is a mild disease, but if the virus persists after a clinically silent myocarditis, it will 
 
eventually lead to irreversible myocardial injury and progressive cardiac dysfunction. 
Although the exact pathogenic mechanism of viral myocarditis is still unclear, the 
damage in myocytes induced by CVB3 are suspected to be caused by autoimmune 
inflammation (Antoniak et al. 2008; Cihakova and Rose, 2008), direct viral cytotoxicities 
(Kearney et al. 2001), and virus-induced apoptosis (Yuan et al. 2003; Martin et al. 2007; 
Carthy et al. 2003). In the clinic, immunosuppressive agents (azathioprine, prednisone, 
and cyclosporine), intravenous immunoglobulin (IVIG), and antiviral agents (interferon, 
pleconaril, and acyclovir), have been used for the treatment of the disease (Brunetti and 
DeSantis, 2008). However, most of these are symptomatic treatment since specific agents 
have not been well established for patients with viral myocarditis of dilated 
cardiomyopathy. Recently, increasingly more active ingredients isolated from traditional 
Chinese medicines have been shown to have antiviral activities against CVB3 (Zhu et al. 
2009; Wang et al. 2009; Su et al. 2006). 
To detect whether the mouse was infected with CVB3, the most specific features are 
the activities of biochemical markers, virus titers of the organs and the histology changes 
of the heart. Death and weight loss are not the overt signs of infection. In this study, we 
treated the BALB/c mice inoculated with CVB3 to induce myocarditis with 
Phyllaemblicin B every day, significantly decreased virus titers in the heart and activities 
of LDH and CK in serum from the CVB3-induced myocarditic mice in comparison with 
those of the infected controls. In addition, damage to the myocardium was relieved, that 
is, the area of necrosis and inflammatory infiltrates of cardiac muscles were much lower 
in the treated groups. These results indicate that the presence of Phyllaemblicin B 
protects myocardial cells against the harmful effects of CVB3 and maintains the levels of 
 
associated enzymes at normal values.  
Apoptotic events occur frequently during CVB3 infection under in vitro as well as in 
vivo conditions. Cardiomyocyte apoptosis has been previously shown to be important for 
both viral replication and virus-induced cardiac pathology after CVB3 infection (Martin 
et al. 2007; Gebhard et al. 1998). A recent study demonstrated that apoptosis was one 
detail of CVB3-induced pathogenesis. Apoptosis in picornavirus-infected cells may be a 
process triggered or accelerated by the virus to facilitate viral progeny release. Activation 
of the apoptotic machinery has been demonstrated in HeLa cells following CVB3 
infection (Carthy et al. 1998). The mitochondria-mediated pathway is commonly believed 
to be associated with apoptosis induced by CVB3. In this pathway, cytochrome c release 
from mitochondria triggers the activation of caspases (Li et al. 1998). Further studies 
demonstrated that in addition to caspase-3 activation, multiple members of the caspase 
family were activated or degraded during CVB3 infection in HeLa cells and in murine 
atrial cardiomyocytes (Carthy et al. 2003). Bcl-2 is an inhibitor of the mitochondrial 
apoptosis pathway. This antiapoptotic molecule acts to inhibit the release of cytochrome 
c thereby blocking caspase activation and the apoptotic process (Kluck et al. 1997). Heat 
shock protein 75 (Hsp75/Grp75/mortalin/TRAP1) is a member of the HSP70 chaperone 
family, which is targeted to mitochondria. Overexpression of Hsp75 improved 
mitochondrial function and protected cells from apoptosis (Xu et al. 2009; Masuda et al. 
2004, Ruiz-Romero et al. 2009). 
In the present study, apoptosis was detected by a FACS assay. The rate of apoptosis in 
cells treated with Phyllaemblicin B was significantly lower than that in infected controls, 
suggesting that Phyllaemblicin B can inhibit apoptosis induced by CVB3. Proteins from 
 
treated and untreated groups were identified and analyzed using a proteomics approach 
based on two-dimensional DIGE and MALDI-TOF/TOF mass spectrometry. Treatment 
with Phyllaemblicin B resulted in upregulated expression of three proteins related to 
apoptosis: glutathione peroxidase 1–isoform 1 (GPX1), succinate dehydrogenase 
(ubiquinone) flavoprotein subunit–mitochondrial (SDHA), and heat shock protein 75 
kDa–mitochondrial precursor (TRAP1). Gpx1, the major isoform of glutathione 
peroxidase, is present in both mitochondria and the cytosol (Esworthy et al. 1997). Gpx1 
mediates mitochondrial protection and suppresses apoptosis progression. Overexpression 
of Gpx1 in the heart attenuates cardiac dysfunction and improves mitochondrial complex 
respiration activity (Gao et al. 2008). SDHA prevents cell death and decreases nuclear 
degradation, mitochondrial disruption, membrane permeability, and caspase activation 
(Laguna et al. 2006). Meanwhile, increased expression of TRAP1 inhibits apoptosis 
induced by CVB3. These results indicate that the antiviral effects of Phyllaemblicin B are 
due to suppression of viral-induced apoptosis.  
  Moreover, caspase-3 and bcl-2 were analyzed for their respective gene and protein 
expression levels. Quantitative real-time RT-PCR and western blot analyses were 
performed in vitro on HeLa cells. Additionally, murine heart tissues were analyzed using 
immunohistochemistry to determine the expression of the two apoptosis-related proteins 
in vivo. We present results showing that the expression of caspase-3 at the gene and 
protein levels is much lower in vitro and in vivo in the Phyllaemblicin B-treated groups. 
Meanwhile, the expression of bcl-2 was much higher in the treated groups. Taken 
together, these data suggest that Phyllaemblicin B can significantly suppress 
virus-induced apoptosis. 
 
Taken together, the present study the first time to demonstrate that Phyllaemblicin B 
has potent activity to inhibiting of CVB3 replication and CVB3-induced apoptosis in 
vitro and in vivo, and significantly inhibits CVB3-induced myocarditis, suggested that 
Phyllaemblicin B is a potential therapeutic agent against CVB3 infection and associated 
viral myocarditis.  
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Inhibitory effects of Phyllaemblicin B on infected HeLa cells. 
 
Drug            TC50 (g/mL)     IC50 (g/mL)      TI 
 
Phyllaemblicin B  50.30 ± 1.59     7.75 ± 0.15      6.49 ± 0.09 
Ribavirin          700 ± 19       182 ± 7.81      3.85 ± 0.11 
 
TC50 is the concentration of the drug showing 50% cytotoxicity. IC50 is the 
concentration of drug required to inhibit 50% of the viral cytopathic effect. TI is the 





Up-regulated proteins in Phyllaemblicin B-treated group (25g/mL). 
 
Protein nameAccession No.Protein scorePI/Mr (Da) Function 
 
SDHA   IPI00305166 531   7.06/72645.3Oxidative phosphorylation 
GPX1   IPI00293975 250   6.15/22027.2Peroxidase 











Fig. 1. The chemical structure of Phyllaemblicin B. 
Fig. 2. Annexin V/PI analysis of apoptosis. (A) HeLa cells infected with CVB3 were 
incubated with 25g/mL Phyllaemblicin B for 24 h, after which the cells were harvested 
and analyzed by FACS. Phyllaemblicin B decreased the proportion of apoptotic cells. (B) 
The apoptosis rates of cells. (a) Normal control, (b) infected control, (c) infected with 
CVB3 and treated with Phyllaemblicin B (25g/mL), (d) infected with CVB3 and treated 
with Ribavirin (125g/mL). *p < 0.05, compared with the infected control. 
 
Fig. 3. 2-DE maps of treated and control groups. (A) Comparison of the protein 
expression patterns between control and Phyllaemblicin B-treated (25g/mL) HeLa cells. 
Circles highlight areas where significant differences in protein expression are present. (B) 
Upregulation of three proteins in the Phyllaemblicin B-treated group. (a) TRAP1,(b) 
SDHA and (c) GPX1. 
 
Fig. 4. The mRNA expression of caspase-3 and bcl-2 in treated and control groups. 
Caspase-3 and bcl-2 mRNA levels expressed as a fraction of the reference gene GAPDH. 
(a) Infected control and (b) Phyllaemblicin B-treated (25g/mL), *p < 0.01, compared 
with infected control. 
 
Fig. 5. Detection of caspase-3 and bcl-2 expression in Phyllaemblicin B-treated 
(25g/mL) and control groups by Western blot analysis. -Actin was examined to 
normalize any differences in loading. 
 
Fig. 6. Effects of Phyllaemblicin B on the activities of LDH and CK in infected mouse 
serum eight days post-infection. (a) Normal control, (b) infected control, (c) Ribavirin 
(125mgkg−1 d−1), (d) Phyllaemblicin B (12mgkg−1 d−1), (e) Phyllaemblicin B (8mg kg-1 
d-1), (f) Phyllaemblicin B (4mg kg−1 d−1), *p < 0.05, compared with infected controls. 
 
Fig. 7. Effects of Phyllaemblicin B on virus titers in BALB/c mice infected with CVB3 at 
eight days post-infection. (a) Normal control, (b) infected control, (c) Ribavirin 
(125mgkg−1 d−1), (d) Phyllaemblicin B (12mgkg−1 d−1), (e) Phyllaemblicin B (8mgkg−1 d−1) 
and (f) Phyllaemblicin B (4mg kg−1 d−1), *p < 0.05, compared with infected controls. 
 
Fig. 8. HE-stained sections of hearts from different groups. (A) Normal control, (B) 
infected control, mononuclear cell inflammation and necrotic cardiomyocyte site were 
indicated by a small black arrow. (C) Ribavirin (125mgkg−1 d−1), (D) Phyllaemblicin B 
(12mgkg−1 d−1), (E) Phyllaemblicin B (8mg kg−1 d−1) , and (F) Phyllaemblicin B (4mgkg−1 
d−1). 
 
Fig. 9. Detection of apoptotic cardiomyocytes with the TUNEL assay. (A) Normal 
control, (B) infected control, apoptosis cell was indicated by a small white arrow. (C) 




Fig. 10. Histological appearance of Coxsackie virus B3-induced murine myocarditis. (A 
and A’) normal control, (B and B’) infected control, (C and C’) Phyllaemblicin B 
(12mgkg−1 d−1). 
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